Qisda's operations in the third quarter showed improvement compared to the second quarter.

Showcase AI capabilities at Healthcare+ Expo Taiwan 2024

Qisda’s (TWSE: 2352) third-quarter operations showed improvement over the previous quarter, with plans to showcase its AI capabilities at the upcoming Healthcare+ Expo Taiwan 2024. Qisda announced its third-quarter financial results, highlighting revenue growth across IT, Medical, and BSG businesses compared to the previous quarter. In particular, 20 affiliated companies of its Medical business groups participate at the upcoming December Healthcare+ Expo to demonstrate advanced AI-integrated smart healthcare solutions. This event showcases Qisda’s commitment to future growth through smart healthcare innovation. 

Qisda held an investor conference on 6th November to explain the third quarter fiscal 2024 operational results and the outlook. The global market is gradually recovering, with the U.S. initiating interest rate cuts, prompting a trend toward monetary easing worldwide. However, the overall economic outlook remains contingent on indicators such as the U.S. presidential election and ongoing regional conflicts.

Qisda's Chairman, Peter Chen, expressed optimism about the medical business, which has maintained a quarterly revenue level of approximately NT$6 billion for six consecutive quarters. Growth has been sustained across hospitals, medical equipment, and pharmaceutical distribution businesses. In addition to advancing BenQ Medical Center's entry into the capital market to accelerate growth, the Board recently approved a public tender offer to increase its stake in NORBEL BABY (Tin Tin Drugstore), further strengthening its position in the medical retail channel.

Qisda’s President, Joe Huang, stated that the IT_Original business demonstrated steady growth, with signs of recovery in the commercial, industrial, and networking markets previously impacted by customer inventory adjustments. Looking forward, Qisda will continue to lean focus and invest in new ventures, collaborating with suppliers to create a resilient and sustainable value chain that addresses the evolving challenges of climate change and market dynamics.

In terms of Q3 performance in each business group, the display business revenue reached a QoQ increase of 5%, with gross margin, operating margin and operating income growing QoQ and YoY as well. Medical business revenue increased by 1%, with gross margin and operating income declined QoQ. NCG business revenue QoQ decreased by 13%, BSG business revenue QoQ increased by 5%, with operating margin and operating income growing QoQ.

Qisda, accompanied by its affiliated companies, will participate in Healthcare+ Expo Taiwan 2024 starting December 5. The group will feature AI healthcare solutions across six key areas, showcasing the latest achievements of 20 companies within Qisda’s healthcare alliance.

Qisda 2024 Q3 Financial Report Highlights:

Revenue: NTD 50.8 billion, up by 1% YoY, up by 2% QoQ.

Gross Profit: NTD 8.512 billion, up by 2% YoY, up by 2% QoQ.

Gross Margin: 16.8%, an increase of 0.2 percentage points year-on-year and 0.1 percentage points quarter-on-quarter, exceeding 16% for six consecutive quarters and setting a 20-year high.

Operating Income: NTD 1.245 billion, down by 8% YoY, up by 5% QoQ.

Operating Income Margin: 2.5%, down by 0.2 percentage points year-on-year, up by 0.1 percentage points quarter-on-quarter, continuous growth for three consecutive quarters.

Net Income: NTD 1.196 billion, a decrease of 23% YoY, an increase of 48% quarter-on-quarter.

Net Income Attributable to Qisda: NTD 1.053 billion, down by 12% year-on-year, up by 59% quarter-on-quarter.

Earnings Per Share (EPS): NTD 0.54.

Earnings Per Share (EPS) for the first three quarters: NTD 1.